NCT04628169

Brief Summary

The main goal of this study is to assess the role of Netrin 1, neogenin and ZEB1 in PAS-associated invasion

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jan 2021

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 9, 2020

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 13, 2020

Completed
2 months until next milestone

Study Start

First participant enrolled

January 1, 2021

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2023

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2023

Completed
Last Updated

September 20, 2024

Status Verified

September 1, 2024

Enrollment Period

2 years

First QC Date

November 9, 2020

Last Update Submit

September 18, 2024

Conditions

Pathophysiology of Placenta Accreta

Keywords

Netrin-1, neogenin,PAS, zeb-1

Outcome Measures

Primary Outcomes (1)

  • impact of netrin-1 in the pathophysiology of placenta accreta spectrum

    1. Evaluation of the immunohistochemical expression of netrin 1 in PAS specimens in comparison with the control placental tissues. 2. Evaluation of the immunohistochemical expression of neogenin in PAS specimens in comparison with the control placental tissues 3. Evaluation of the immunohistochemical expression of ZEB1 in PAS specimens in comparison with the control placental tissues. 4. Correlate their immunohistochemical expression with the demographic parameters and assess the correlation between their expression in PAS specimens.

    baseline

Study Arms (2)

group A

30 placental specimens of PAS

Other: no intervention applied

group B

30 placental specimens of heaithy women with normal pregnancy

Other: no intervention applied

Interventions

no intervention appliedOTHER

no intervention applied

group Agroup B

Eligibility Criteria

Age20 Years - 40 Years
Sexfemale(Gender-based eligibility)
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

30 PAS specimens and 30 placental specimens from matched control.

You may qualify if:

  • PAS patients who underwent hysterectomy to allow proper pathologic grading of PAS

You may not qualify if:

  • patients with fundal and middle anterior or posterior placenta,
  • pregnancy associated with morbid conditions such as hypertension, diabetes mellitus, autoimmune disease, cardiac disease, renal disease, history of anemia, blood transfusion, other blood diseases and endocrinal disease; fetal distress or intrauterine growth retardation.
  • uterine scar pregnancies were excluded

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hanaa Mohammed Mohammed Sayed

Asyut, Egypt

Location

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assistant lecturer

Study Record Dates

First Submitted

November 9, 2020

First Posted

November 13, 2020

Study Start

January 1, 2021

Primary Completion

January 1, 2023

Study Completion

July 1, 2023

Last Updated

September 20, 2024

Record last verified: 2024-09

Locations

EG(1)